Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efavirenz + tenofovir disoproxil fumarate + telaprevir
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of three antiviral drugs: efavirenz, tenofovir disoproxil fumarate, and telaprevir. Efavirenz is a non-nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, an enzyme necessary for viral replication. Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor that also inhibits HIV reverse transcriptase by competing with natural substrates and causing DNA chain termination. Telaprevir is a protease inhibitor that targets the hepatitis C virus by reversibly binding to the NS3/4A serine protease, preventing cleavage of viral polyproteins required for HCV replication[2][6]. This combination would theoretically have activity against both HIV and hepatitis C virus if used together; however, this specific triple combination does not represent an approved or standard regimen for either infection.
- Brand names
- Sustiva (efavirenz)Viread (tenofovir disoproxil fumarate)Incivek (telaprevir)
- Other names
- EFV (efavirenz)TDF (tenofovir disoproxil fumarate)TVR (telaprevir)
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseNS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on efavirenz + tenofovir disoproxil fumarate + telaprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efavirenz + tenofovir disoproxil fumarate + telaprevir.